Search

Your search keyword '"Pedro David Delgado‐López"' showing total 6 results
Start Over Author "Pedro David Delgado‐López" Language english
6 results on '"Pedro David Delgado‐López"'

1. A clinically compatible drug‐screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

Author

Lucía Zhu, Diana Retana, Pedro García‐Gómez, Laura Álvaro‐Espinosa, Neibla Priego, Mariam Masmudi‐Martín, Natalia Yebra, Lauritz Miarka, Elena Hernández‐Encinas, Carmen Blanco‐Aparicio, Sonia Martínez, Cecilia Sobrino, Nuria Ajenjo, Maria‐Jesus Artiga, Eva Ortega‐Paino, Raúl Torres‐Ruiz, Sandra Rodríguez‐Perales, RENACER, Riccardo Soffietti, Luca Bertero, Paola Cassoni, Tobias Weiss, Javier Muñoz, Juan Manuel Sepúlveda, Pedro González‐León, Luis Jiménez‐Roldán, Luis Miguel Moreno, Olga Esteban, Ángel Pérez‐Núñez, Aurelio Hernández‐Laín, Oscar Toldos, Yolanda Ruano, Lucía Alcázar, Guillermo Blasco, José Fernández‐Alén, Eduardo Caleiras, Miguel Lafarga, Diego Megías, Osvaldo Graña‐Castro, Carolina Nör, Michael D Taylor, Leonie S Young, Damir Varešlija, Nicola Cosgrove, Fergus J Couch, Lorena Cussó, Manuel Desco, Silvana Mouron, Miguel Quintela‐Fandino, Michael Weller, Joaquín Pastor, Manuel Valiente, Adolfo de la Lama‐Zaragoza, Lourdes Calero‐Felix, Concepcion Fiaño‐Valverde, Pedro David Delgado‐López, Antonio Montalvo‐Afonso, Mar Pascual‐Llorente, Ángela Díaz‐Piqueras, SH Nam‐Cha, Cristina Barrena López, Gerard Plans Ahicart, Elena Martínez‐Saez, Santiago Ramón y Cajal, and Pilar Nicolás

Subjects
drug‐screen, metastasis, organotypic cultures, patient‐derived, resistance, Medicine (General), R5-920, Genetics, QH426-470
Abstract

Abstract We report a medium‐throughput drug‐screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug‐screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere.

Published
2022
Full Text
View/download PDF

2. External validation and recalibration of an incidental meningioma prognostic model – IMPACT: protocol for an international multicentre retrospective cohort study

Author

Julie Woodfield, Boris Krischek, Giles Critchley, Damian Holliman, Angelos Kolias, Thomas Santarius, Ola Rominiyi, Michael McDermott, Michael D Jenkinson, Jörg-Christian Tonn, Mohsen Javadpour, Andrea Saladino, Tiit Illimar Mathiesen, Rory Piper, Michael Vogelbaum, Chaya Brodie, Sara Venturini, Daniel M Fountain, Roland Goldbrunner, Elliot Tilling, Felix Sahm, Priscilla Brastianos, Rory J Piper, Antonio Santoro, Sylvia Kurz, Pierfrancesco Lapolla, Andrea Mingoli, Jennifer Brown, Debraj Mukherjee, Simon Walling, Andrew Morokoff, Patrick Wen, Ghazaleh Tabatabai, Jill Barnholtz-Sloan, Ryan K Mathew, Alexander Smedley, Helen Shih, William Taylor, Minh Nguyen, Bryony Ford, Samantha J Mills, Tamara Ali, Ruwanthi Kolamunnage-Dona, Josephine Jung, Muhammed Elhadi, Erminia Albanese, Aswin Chari, David Rowland, Melissa Gough, Michael Cearns, Simon Lammy, Yasir Chowdhury, Christian Mawrin, Mahmoud Saleh, Jens Schittenhelm, Farshad Nassiri, Raymond Huang, Pietro Familiari, Manfred Westphal, Warren Selman, Daniel Brown, Nathan McSorley, Oliver Hanemann, Richard Pullicino, Francesco Gaillard, Mirjam Renovanz, Chris Barrett, Christine Jungk, Aaron Cohen-Gadol, Javier Martín-Alonso, Gelareh Zadeh, Hytham Hamid, Abdurrahman I Islim, Christopher P Millward, Shaveta Mehta, Usama Ali, Shelli Diane Koszdin, Theo Georgious, Andrew R Brodbelt, Mohamed Abdelsadg, Suhaib Abualsaud, Amro Abuleil, Kevin Agyemang, Hanan Akbari, Likhith Alakandy, Clarissa Alfonso, Arousa Ali, Michael Amoo, Mohamed A. R. Arbab, Mutiu Asha, Kareem Austin, Khaled Badran, Jarnail Bal, Parameswaran Bhattathiri, Paul M. Brennan, Andrew R. Brodbelt, Ferran Brugada-Bellsolà, Placido Bruzzaniti, Annabel Butcher, Rory S. Cairns, Michael Canty, Sachiv Chakravarti, Rebecca Chave-Cox, Anna Craig-McQuade, Peter Crossley, Elizabeth Culpin, Alessia D'Amico, Bassam Dabbous, Pedro David Delgado-López, Mohamed Draz, Katharine J. Drummond, Rusiru T. Ekanayaka, Ibrahim Elmaadawi, Omar Elmandouh, Mazin Elsharif, Daisy Evans, Andreas Fahlström, Fleur L. Fisher, Daniel M. Fountain, Keiko Fox, Chloé Gelder, Shamayitri Ghosh, Aimee Goel, Athanasios Grivas, Andrew Gvozdanovic, Allan Hall, Liv Hartrick, Samih Hassan, Jack Henry, Abdurrahman I. Islim, Asgeir S. Jakola, Michael D. Jenkinson, Sanjeeva Jeyaretna, Adrian Jimenez, Andranik Kahramanian, Neeraj Kalra, David O. Kamson, Oliver Kennion, Adham M. Khalafallah, Sarah Kingdon, Howra Ktayen, Aditaya Kumar, Jun Yi Lau, Jing Xian Lee, Ryan Leyden, Patricia Littlechild, Sophie Liu, Darmanin Lora-Kay, Vivia Lung, Stephen T. Magill, Hani J. Marcus, Fawaz E. Marhoom, Ryan K. Mathew, Calan Mathieson, Tobias Mederer, Torstien R. Meling, Samantha J. Mills, Christopher P. Millward, Mujtaba Mohammad, Amir H. Zamanipoor Najafabadi, Olivia Näslund, Imran Noorani, Gildas Patet, Omar N. Pathmanaban, Andrea Perera, Amit Persad, See Yung Phang, Rory J. Piper, Jonathan Pollock, Benjamin Price, Martin Proescholdt, James Robins, Bobby Sachdev, Fozia Saeed, Ieva Sataite, Antony Kevin Scafa, Verena Schadewaldt, Syed Wajahat Shah, Mustafa El Sheikh, Zenab Sher, Bente Sandvei Skeie, Agbolahan Sofela, Jerome St George, Torbjørn Strømsnes, Nigel Suttner, Philip Theodosopoulos, Manjul Tripathi, Ismail Ughratdar, James Ulrich, Adithya Varma, Anil Varma, Maria Velicu, Esther Wu, Jacob Young, Giuseppa Zancana, Catherine Zhang, Karolyn Au, Felix Behling, Linda Bi, Nicholas Butowski, Ana Castro, Marta Couce, Francesco Dimeco, Katherine J. Drummond, Ian Dunn, Craig Erker, Michelle Felicella, Eva Galanis, Norbert Galldiks, Caterina Giannini, Christel Herold-Mende, Luke Hnenny, Craig Horbinski, Gerhard Jungwirth, Timothy Kaufmann, Daniel Lachance, Christian Lafougere, Katrin Lamszus, Serge Makarenko, Tathiana Malta, Jennifer Moliterno-Gunel, HK Ng, Houtan Noushmehr, Arie Perry, Laila Poisson, Bianco Pollo, Aditya Ragunathan, David Raleigh, Franz Ricklefs, Antonio Santacroce, Christian Schichor, Nils Schimdt, Andrew Sloan, Matija Snuderl, Jim Snyder, Erik Sulman, Suganth Suppiah, Marcos Tatagiba, Marco Timmer, Andreas Von Deimling, Tobias Walbert, Justin Z. Wang, Stephen Yip, Gabriel Zada, Viktor Zherebitskiy, and Michael T.C. Poon

Subjects
Medicine
Published
2022
Full Text
View/download PDF

3. Telemedicine in the Management of Parkinson’s Disease: Achievements, Challenges, and Future Perspectives

Author

Esther Cubo and Pedro David Delgado-López

Subjects
telemedicine, teleneurology, telecare, movement disorders, tele-education, new technology, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Background: As the global population grows, there is an increasing demand for neurologic consultation that prompts new ways to reach more patients. Telemedicine can provide an accessible, cost-effective, and high-quality healthcare services. Objectives: In this article, we highlight recent developments, achievements, and challenges regarding outcomes, clinical care, tele-education, teletreatment, teleresearch, and cybersecurity for telemedicine applied to Parkinson´s disease (PD) and other neurological conditions. Results: A growing body of evidence supports the feasibility and effectiveness of telemedicine tools for PD and other movement disorders. Outcome variables regarding satisfaction and efficacy in clinical care and specific issues about education, research, and treatment are reviewed. Additionally, a specific legal framework for teleconsultation has been developed in some centers worldwide. Yet, the implementation of telemedicine is conditioned by the limitations inherent to remote neurological examination, the variable computer usage literacy among patients, and the availability of a reliable internet connection. At present, telemedicine can be considered an additional tool in the clinical management of PD patients. Conclusions: There is an increasing use of remote clinical practice regarding the management of PD and other neurological conditions. Telemedicine is a new and promising tool aimed at special settings and subpopulations.

Published
2022
Full Text
View/download PDF

4. Tremor Control Devices for Essential Tremor: A Systematic Literature Review

Author

Victoria Castrillo-Fraile, Elena Casas Peña, José María Trejo Gabriel y Galán, Pedro David Delgado-López, Carla Collazo, and Esther Cubo

Subjects
essential tremor, voluntary movement, devices, neuroprosthesis, orthosis, upper limb, Diseases of the musculoskeletal system, RC925-935, Neurology. Diseases of the nervous system, RC346-429
Abstract

Background: There is a growing interest in nonpharmacological approaches for essential tremor (ET), including tremor cancelation devices. However, the true efficacy of such devices in ET remains unclear. Methods: A systematic literature review was conducted using standardized criteria regarding efficacy and comfortability. Devices focused on design or experimental testing in which tremor was simulated in a robot were excluded. Results: Out of 324 articles initially identified, 12 articles were included. Orthoses using biomechanical loading and neuromodulation with electrical stimulation, and external tremor cancelation devices, were the main interventions used to suppress tremor. All devices were designed to control tremor of the upper limbs at different anatomical locations. Overall, an average tremor attenuation of 50–98% was reported (level of evidence III). Interference with voluntary movements and portability was described as the main drawback. Discussion: In conclusion, this review highlights the growing interest in emerging tremor control devices and the importance of assessing comfort without affecting voluntary movements. However, the level of evidence regarding the efficacy of these tremor control devices remains low. An integrated multidisciplinary combination approach of engineering, robotics, physiology, physiotherapy, and clinical assessment is needed to improve the quality of non-pharmacological interventions for ET.

Published
2019
Full Text
View/download PDF

5. Is Restless Legs Syndrome Associated with an Increased Risk of Mortality? A Meta-Analysis of Cohort Studies

Author

Esther Cubo, Cesar Gallego-Nieto, Miren Elizari-Roncal, Teresa Barroso-Pérez, Carla Collazo, Sara Calvo, and Pedro David Delgado-López

Subjects
Restless legs syndrome, mortality, survival, epidemiology, cohorts, sleep disorder, Diseases of the musculoskeletal system, RC925-935, Neurology. Diseases of the nervous system, RC346-429
Abstract

Background: Restless legs syndrome (RLS) is a common sleep disorder,. although controversial, growing evidence relates the presence of RLS to an increased risk of mortality, mainly due to cardiovascular events. The aim of this article was to review the role of RLS as a risk factor of mortality according to independent cohort studies. Methods: We performed a literature review via PubMed database for articles relating RLS and mortality. We used the random-effects model to calculate the pooled effect estimates on mortality. Heterogeneity between studies was assessed using quantitative and qualitative analysis. Results: Out of 100 articles identified, 13 were finally included. Although studies were heterogeneous (p = 0.001), no significant publication bias was found. When all cohort studies were considered, the random-effects model yielded a significantly increased risk of mortality in RLS versus non-RLS patients (13 studies, hazard ratio [HR] = 1.52, 95% confidence interval [CI] 1.28–1.80). However, this association was not statistically significant when only cohort studies using the international RLS diagnostic criteria were considered (5 studies, HR = 1.63, 95% CI 0.94–2.81). Discussion: The results of this meta-analysis suggest that RLS seems to be a risk factor of mortality, although this association is conditioned by the diagnostic criteria used in the studies. Future long-term follow-up standardized mortality studies are needed to address this important question that carries potential impact on population global health.

Published
2019
Full Text
View/download PDF

6. Author Response to Letter to the Editor

Author

Victoria Castrillo-Fraile, Elena Casas Peña, José María Trejo Gabriel y Galán, Pedro David Delgado-López, Carla Collazo, and Esther Cubo

Subjects
essential tremor, orthesis, non-pharmacological treatment, Diseases of the musculoskeletal system, RC925-935, Neurology. Diseases of the nervous system, RC346-429
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results